ACRX AcelRx Pharmaceuticals Inc.

1.32
+0.01  (+1%)
Previous Close 1.31
Open 1.33
Price To Book -2.54
Market Cap 106,143,650
Shares 80,411,856
Volume 578,419
Short Ratio
Av. Daily Volume 1,047,866
Stock charts supplied by TradingView

NewsSee all news

  1. AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

    REDWOOD CITY, Calif., March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for

  2. AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals

    REDWOOD CITY, Calif., March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for

  3. Tetraphase Pharmaceuticals and AcelRx Pharmaceuticals Enter into Definitive Merger Agreement

    AcelRx to Acquire Tetraphase in an all-stock transaction Tetraphase equity holders to own 14.6% of the combined company and receive Contingent Value Rights worth up to $12.5 Million Acquisition Expected to Close in

  4. AcelRx to Announce Fourth Quarter 2019 Results on Monday, March 16th, 2020

    REDWOOD CITY, Calif., March 11, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and annual financial results before

  5. AcelRx Announces Confirmed Timing of Department of Defense Milestone C Meeting for April

    REDWOOD CITY, Calif., March 10, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released August 15 2016
ARX-04 (SAP302)
Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury
FDA Approval announced November 2, 2018.
DSUVIA (ARX-04)
Moderate-to-severe acute pain following a surgical procedure
CRL Jul 26 2014. NDA resubmission planned.
Zalviso
Post-operative pain following open abdominal surgery and hip or knee replacement surgery

Latest News

  1. AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

    REDWOOD CITY, Calif., March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for

  2. AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals

    REDWOOD CITY, Calif., March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for

  3. Tetraphase Pharmaceuticals and AcelRx Pharmaceuticals Enter into Definitive Merger Agreement

    AcelRx to Acquire Tetraphase in an all-stock transaction Tetraphase equity holders to own 14.6% of the combined company and receive Contingent Value Rights worth up to $12.5 Million Acquisition Expected to Close in

  4. AcelRx to Announce Fourth Quarter 2019 Results on Monday, March 16th, 2020

    REDWOOD CITY, Calif., March 11, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and annual financial results before

  5. AcelRx Announces Confirmed Timing of Department of Defense Milestone C Meeting for April

    REDWOOD CITY, Calif., March 10, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for

  6. AcelRx Announces Agreement for an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Spine Surgery

    REDWOOD CITY, Calif., March 6, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for

  7. AcelRx Announces Year-End 2019 Metrics and Provides Corporate Updates

    REDWOOD CITY, Calif., Jan. 13, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for

  8. AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Dosing and Efficacy Data on Sufentanil Sublingual 30 mcg Tablets

    REDWOOD CITY, Calif., Nov. 13, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in

  9. AcelRx Pharmaceuticals Reports Third Quarter 2019 Financial Results

    REDWOOD CITY, Calif., Nov. 6, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use

  10. AcelRx Pharmaceuticals to Present at Credit Suisse 28th Annual Healthcare Conference

    REDWOOD CITY, Calif., Nov. 5, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in

  11. AcelRx to announce third quarter 2019 results and provide an update on the company's business on Wednesday, November 6th, 2019

    REDWOOD CITY, Calif., Oct. 28, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close